A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

NCT03099187 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

253

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Diseases, Interstitial

Interventions

DRUG: Pirfenidone
DRUG: Placebo

Sponsor

Hoffmann-La Roche